Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-05-10-Speech-2-313-750"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-05-10"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20110510.60.2-313-750"2
lpv:hasSubsequent	lp_eu:2011-05-10-Speech-2-313-8752
lpv:speaker	lp:Juozas Imbrasas2
lpv:spokenAs	member; TRAN (2009-07-16--2012-01-18)3 member; Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia Parliamentary Cooperation Committees (2009-09-16--2014-06-30)3 member; EFD (2009-07-14--2014-06-30)3 member; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3 unknown; Partija Tvarka ir teisingumas (2009-07-14--2014-06-30)3 member; Delegation for relations with the Korean Peninsula (2009-09-16--2012-02-14)3 member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 member; REGI (2009-07-16--2012-01-18)3
lpv:translated text	"I endorsed this document, because the Committee responsible decided to approve the closure of the accounts of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2009. The Court of Auditors stated that it has obtained reasonable assurances that the annual accounts for the financial year 2009 are reliable and that the underlying transactions are legal and regular. The Innovative Medicines Initiative Joint Undertaking was set up in February 2007 to significantly improve the efficiency and effectiveness of the drug development process with the long-term aim of helping the pharmaceutical sector to produce more effective and safer innovative medicines. The Joint Undertaking is in a start-up phase and had not yet fully established its internal control and financial reporting systems by the end of 2009. At the same time, the Joint Undertaking final 2009 budget included commitment appropriations of EUR 82 000 000 and payment appropriations of EUR 82 000 000, and the utilisation rates for commitment and payment appropriations were 97% and 1% respectively."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph